Pharmaceutical composition for preventing or treating alcoholic and nonalcoholic fatty liver disease

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating fatty liver disease, containing the ATPase inhibitory factor 1 (IF1) as an active ingredient, and the composition can be usefully used for the purpose of preventing and treating fatty liver disease, as the composition protects hepatocytes from toxicity due to alcohol; reduces the formation of fatty liver by suppressing lipid accumulation in liver tissue and an increase in the blood lipid concentration caused by excessive nutrition; suppresses liver fibrosis and inflammatory response; and increases the proportion of beneficial bacteria in the gut microbiome.

1 . A method for treating alcoholic and non-alcoholic fatty liver disease, comprising:
 administering a pharmaceutical composition comprising ATPase inhibitory factor 1 (IF1) as an active ingredient to an individual in need of treatment.   
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition protects hepatocytes from toxicity caused by alcohol. 
     
     
         3 . The method of  claim 1 , wherein the pharmaceutical composition suppresses an increase in blood lipid concentration. 
     
     
         4 . The method of  claim 1 , wherein the pharmaceutical composition suppresses lipid accumulation in liver tissue. 
     
     
         5 . The method of  claim 1 , wherein the pharmaceutical composition suppresses liver fibrosis. 
     
     
         6 .- 11 . (canceled)